Advances in Immuno-Oncology Therapeutics for Metastatic Triple-Negative Breast Cancer

Engage with this series of 4 focused ClinicalThought commentaries to gain expert insight on how to optimally integrate immunotherapy into the care of your patients with metastatic TNBC.
Sarah Donahue, MPH, NP
David B. Page, MD
Hope S. Rugo, MD
Peter Schmid, MD, PhD, FRCP

Module

Review the latest developments in immuno-oncology strategies for managing metastatic TNBC with this set of expert commentaries, including optimal use of immune checkpoint inhibition, management of immune-related toxicities, and future directions.

Sarah Donahue, MPH, NP David B. Page, MD Hope S. Rugo, MD Peter Schmid, MD, PhD, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 14, 2020 Expired: May 13, 2021

ClinicalThought

Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to identify and manage the unique adverse events associated with immune checkpoint inhibition? Read this expert commentary to get up to speed.

Sarah Donahue, MPH, NP Released: March 16, 2020

Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to best use this agent in your clinical practice? Read this expert commentary to get up to speed.

Hope S. Rugo, MD Released: April 2, 2020

Are you aware of the latest data on immune checkpoint inhibition for the treatment of early-stage TNBC? Read my thoughts on the promise of this strategy for our patients with this disease.

Peter Schmid, MD, PhD, FRCP Released: April 17, 2020

Are you aware of new strategies using combination immunotherapy in the treatment of metastatic TNBC? Read my thoughts on this promising approach to potentially improve response to immunotherapy in these patients.

David B. Page, MD Released: April 27, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue